Aclaris reports positive Phase 1 MAD data for ATI-2138; advances to Phase 2a in ulcerative colitis

Aclaris Therapeutics, Inc.

ATI-2138 well tolerated in 60-subject MAD trial; no serious adverse events; mild headache and diarrhea only events in >1 subject.
Dose-proportional PK and near-maximal inhibition of ITK and JAK3 biomarkers achieved at 30 mg total daily dose.
Company to start Phase 2a proof-of-concept in ulcerative colitis in early 2024; evaluating second PoC in another T-cell mediated disease.
CEO highlights KINect discovery engine; upcoming Phase 2 data for zunsemetinib (RA) and ATI-1777 (atopic dermatitis) expected late 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.